Investigating if hydroxychloroquine can prevent complications in pregnancies affected by lupus.
Can hydroxychloroquine prevent preeclampsia and preterm delivery in lupus pregnancy?
This study is looking at whether taking hydroxychloroquine can help pregnant women with lupus lower their chances of developing preeclampsia and having their babies early, using information from women in the US and Sweden to find out more about how to keep them and their babies healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10889183 on NIH RePORTER |
What this research studies
This research focuses on pregnant women with systemic lupus erythematosus and aims to determine if hydroxychloroquine (HCQ) can reduce the risk of preeclampsia and preterm delivery. The study will analyze data from large international populations, including the US and Sweden, to assess the effectiveness of HCQ in preventing adverse pregnancy outcomes. By examining prescription data and other critical factors, the research seeks to provide insights into the management of lupus during pregnancy and improve health outcomes for these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are pregnant women diagnosed with systemic lupus erythematosus.
Not a fit: Patients without a diagnosis of lupus or those not currently pregnant may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved pregnancy outcomes for women with lupus, reducing the incidence of preeclampsia and preterm delivery.
How similar studies have performed: Previous pilot studies have shown promising results regarding the use of hydroxychloroquine in preventing adverse outcomes in lupus pregnancies, indicating a potential for success in this larger study.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Simard, Julia F — Stanford University
- Study coordinator: Simard, Julia F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.